Date: 2016-05-06
Type of information: Nomination
Compound:
Company: Epizyme (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On May 6, 2016, Epizyme announced that it has expanded its senior leadership team with the addition of Matthew Ros , who joins the company as Chief Operating Officer. In this role, Mr. Ros will be responsible for directing and operationalizing Epizyme's launch readiness efforts for tazemetostat, and will report to Epizyme's President and Chief Executive Officer, Robert Bazemore . Matthew Ros comes to Epizyme from Sanofi, where he was most recently Chief Operating Officer/Global Head of the Oncology Business Unit. While overseeing its $1.4 billion solid tumor and hematology franchise, he led its most recent restructuring and significantly contributed to the company's revised business strategy. Prior to this role, Mr. Ros served in Genzyme's Rare Disease business, leading its second largest franchise in Pompe Disease as its Vice President and Franchise head.
Financial terms:
Latest news:
